Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
NCT05120271 · View on ClinicalTrials.gov ↗
Study Summary
This is a first-in-human (FIH), Phase 1/2, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in subjects with glypican-3 positive (GPC3+) advanced solid tumors.
Conditions Studied
Interventions
- BIOLOGICAL CAR-GPC3 T Cells
Study Locations (8)
Other
- Beatson Institute for Cancer Research Wolfson Wohl Cancer Research Centre — Glasgow
- University College London Hospitals NHS Foundation Trust — London
- The Royal Marsden NHS Foundation Trust — London
Texas
- Baylor Scott and White Research Institute — Dallas
- University of Texas MD Anderson Cancer Center — Houston
California
- Hoag Hospital Newport Beach — Newport Beach
Washington
- Fred Hutchinson Cancer Center - Seattle Cancer Care Alliance (SCCA) Location — Seattle
Wisconsin
- Froedtert and Medical College of Wisconsin — Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2022-10-26 |
| Est. Completion | 2042-12 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05120271
The ClinicalTrials.gov registry entry for NCT05120271 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sotio Biotech, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention — of which CAR-GPC3 T Cells is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05120271 reports 8 study locations spanning 5 distinct geographic areas — top geographies include Other, Texas, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05120271 about?
NCT05120271 is a clinical study titled "BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors". This is a first-in-human (FIH), Phase 1/2, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in subjects with glypican-3 positive (GPC3+) advanced solid tumors.
What is the current status of trial NCT05120271?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2022-10-26. Estimated completion is 2042-12.
What conditions does trial NCT05120271 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Merkel Cell Carcinoma, Squamous Cell Carcinoma of the Lung, Myxoid/Round Cell Liposarcoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05120271?
The interventions under investigation include: CAR-GPC3 T Cells (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05120271?
This trial is sponsored by Sotio Biotech, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05120271 being conducted?
This trial has 8 study locations across California, Texas, Washington, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.